bluebird bio Inc (NASDAQ:BLUE) – Stock analysts at William Blair issued their FY2020 earnings per share (EPS) estimates for shares of bluebird bio in a research report issued to clients and investors on Tuesday, December 4th. William Blair analyst R. Prasad expects that the biotechnology company will post earnings of ($11.02) per share for the year. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for bluebird bio’s FY2021 earnings at ($6.06) EPS and FY2022 earnings at ($2.09) EPS.

Several other equities research analysts have also weighed in on BLUE. BidaskClub raised bluebird bio from a “strong sell” rating to a “sell” rating in a research report on Friday, November 30th. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating in a research note on Friday, November 30th. Maxim Group reissued a “hold” rating on shares of bluebird bio in a research note on Monday, December 3rd. Piper Jaffray Companies cut bluebird bio from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $240.00 to $120.00 in a research note on Thursday. Finally, Oppenheimer reissued a “hold” rating on shares of bluebird bio in a research note on Tuesday. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $194.80.

Shares of NASDAQ BLUE opened at $102.23 on Friday. bluebird bio has a 1-year low of $100.99 and a 1-year high of $236.17. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -13.26 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The firm had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period last year, the company earned ($1.73) earnings per share. The firm’s revenue for the quarter was up 49.2% on a year-over-year basis.

A number of hedge funds have recently made changes to their positions in BLUE. Aperio Group LLC grew its holdings in shares of bluebird bio by 9.7% during the second quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock valued at $1,145,000 after buying an additional 646 shares during the last quarter. TD Asset Management Inc. grew its holdings in shares of bluebird bio by 7.8% during the second quarter. TD Asset Management Inc. now owns 50,886 shares of the biotechnology company’s stock valued at $7,987,000 after buying an additional 3,700 shares during the last quarter. Public Employees Retirement Association of Colorado grew its holdings in shares of bluebird bio by 26.1% during the second quarter. Public Employees Retirement Association of Colorado now owns 8,976 shares of the biotechnology company’s stock valued at $1,409,000 after buying an additional 1,858 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of bluebird bio by 1.9% during the second quarter. Jennison Associates LLC now owns 512,740 shares of the biotechnology company’s stock valued at $80,475,000 after buying an additional 9,677 shares during the last quarter. Finally, Frontier Capital Management Co. LLC grew its holdings in shares of bluebird bio by 84.2% during the second quarter. Frontier Capital Management Co. LLC now owns 94,846 shares of the biotechnology company’s stock valued at $14,886,000 after buying an additional 43,365 shares during the last quarter.

In related news, Director James Mandell sold 1,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total transaction of $150,770.00. Following the completion of the transaction, the director now owns 1,568 shares of the company’s stock, valued at $236,407.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Susanna Gatti High sold 1,890 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $113.83, for a total value of $215,138.70. Following the transaction, the chief operating officer now directly owns 15,610 shares of the company’s stock, valued at approximately $1,776,886.30. The disclosure for this sale can be found here. Insiders have sold 21,490 shares of company stock valued at $2,901,186 in the last ninety days. Company insiders own 3.00% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: Bear Market

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.